FDA Approves APP's Abraxane Paclitaxel Formulation
This article was originally published in The Pink Sheet Daily
Executive Summary
American Pharmaceutical Partners will submit survival data and pharmacokinetic data in subjects with hepatic impairment for Abraxane as part of the company's Phase IV commitments. APP hopes to position Abraxane as safer and more effective than Bristol's Taxol and paclitaxel generics.
You may also be interested in...
Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details
Veteran Merck scientist recruited for personalized-medicine push.
Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details
Veteran Merck scientist recruited for personalized-medicine push.
Abraxane vs. Taxotere: Abraxis Prepares To Go Head-To-Head In Phase III Trials
Study comparing Abraxane to Sanofi’s Taxotere for first-line breast cancer will start in second half, along with lung cancer and melanoma studies.